Merck Acquisitions: How Merck Built Its Business Through M&A

Merck acquisitions show how one of the world’s leading biopharmaceutical companies has used mergers and acquisitions to expand its medicine pipeline, strengthen its biotechnology capabilities, and enter new therapeutic markets. From 1993 to 2025, Merck completed 29 acquisitions with a total disclosed deal value of about $67.4 billion and an average disclosed deal size of roughly $2.3 billion.

The company’s acquisition activity has been heavily concentrated in biotechnology. Biotechnology accounts for 26 deals, health care for 16, medical businesses for 9, therapeutics for 8, and pharmaceuticals for 7. That concentration tells a clear story: Merck has used M&A mainly to acquire scientific platforms, drug candidates, clinical programs, and specialist teams.

The most recent listed acquisition is Verona Pharma, announced in July 2025 for approximately $10 billion. Verona is a biotechnology company focused on chronic respiratory diseases, and the transaction added Ohtuvayre, also known as ensifentrine, to Merck’s cardio-pulmonary portfolio.

Merck’s acquisition record is not a simple list of companies. It is a map of the company’s long-term strategy: strengthen oncology, diversify beyond mature franchises, add new growth drivers, and buy promising science before competitors do.

What Is Merck?

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases. Known as MSD outside the United States and Canada, the company operates across human health, vaccines, oncology, specialty medicines, and animal health.

Its acquisition history shows a strong focus on therapeutic innovation. Merck has bought companies working on cancer drugs, immuno-oncology, autoimmune and inflammatory diseases, respiratory conditions, eye disease, bone marrow disorders, chronic pain, infectious disease vaccines, and animal intelligence solutions.

This makes Merck different from companies that acquire mainly for manufacturing capacity or distribution. While those areas matter, Merck’s M&A record is overwhelmingly science-led. Many targets were clinical-stage or biotechnology companies with promising programs rather than large commercial pharmaceutical businesses.

That strategy is common in modern pharma. Large drugmakers need new medicines to offset patent expirations, strengthen pipelines, and enter fast-growing therapeutic areas. Smaller biotech companies often create the science, while larger companies provide late-stage development, regulatory scale, manufacturing, and global commercialization.

Why Merck Acquisitions Matter

Merck acquisitions matter because they show how major pharmaceutical companies manage pipeline risk. Drug development is expensive, uncertain, and slow. A company can invest for years in research and still fail in clinical trials. M&A allows a drugmaker to buy external innovation and reduce dependence on internal discovery alone.

This is especially important for Merck because large pharmaceutical companies must prepare for future patent cliffs. When a blockbuster medicine loses exclusivity, revenue can decline sharply as generics or biosimilars enter the market. Acquisitions help fill future revenue gaps by adding new assets and therapeutic platforms.

The Verona Pharma deal is a strong example. Public reporting and Merck’s own announcement described the acquisition as a move to expand the company’s cardio-pulmonary portfolio, while industry coverage linked the deal to Merck’s broader effort to diversify beyond Keytruda, its major cancer franchise.

Merck acquisitions also matter because they reveal where the company sees future medical and commercial opportunity. Oncology, respiratory disease, ophthalmology, autoimmune disease, rare blood disorders, and animal health all appear in the record. These are areas where unmet medical need, scientific progress, and large patient populations can create significant value.

Full List of Merck Acquisitions

The table below summarizes 20 notable Merck acquisitions from the available acquisition record.

Merck Acquisitions Timeline

2014: Clinical-Stage Oncology Expansion

In 2014, Merck acquired OncoEthix for $375.0 million. OncoEthix was a clinical-stage biotechnology company developing cancer drugs.

This deal reflected a key Merck theme: oncology pipeline expansion. Cancer drug development is one of the most competitive areas in global pharma. By acquiring clinical-stage assets, Merck could strengthen its oncology research base and broaden the number of potential therapies in development.

2015: Early Cancer Immunotherapy

In 2015, Merck acquired cCAM Biotherapeutics for $95.0 million. cCAM was a pre-clinical-stage company developing cancer immunotherapies.

The acquisition fit Merck’s broader immuno-oncology strategy. Cancer immunotherapy became one of the most important areas in drug development during the 2010s, and Merck’s acquisition history shows repeated investment in this field.

2016: Chronic Pain and Neurology-Linked Drug Development

In 2016, Merck acquired Afferent Pharmaceuticals for $1.3 billion. Afferent was a clinical-stage biopharmaceutical company developing medicines to treat chronic pain.

This acquisition expanded Merck beyond oncology into a difficult therapeutic area with major patient need. Chronic pain treatment has long been challenging because drug developers must balance effectiveness, safety, and long-term patient risk.

2017: RNA Therapeutics and Immuno-Oncology

In 2017, Merck acquired Rigontec for $465.0 million. Rigontec was developing RIG-I targeting RNA therapeutics and novel immuno-oncology treatment options.

The deal reinforced Merck’s interest in immune system modulation and cancer therapy. RNA therapeutics and immuno-oncology platforms were becoming increasingly important as researchers looked for new ways to activate immune responses against tumors.

2018: Animal Intelligence and Therapeutic Biotechnology

In 2018, Merck acquired Viralytics and Antelliq. Viralytics added biotechnology assets linked to therapeutic development. Antelliq, acquired for $2.1 billion, designed, produced, and distributed animal intelligence solutions for the management of livestock, pets, and fish.

Antelliq was notable because it extended Merck’s acquisition activity beyond human medicine. It strengthened the company’s animal health and intelligent systems capabilities. The deal also showed that Merck’s M&A strategy includes technology-enabled animal health, not only human pharmaceuticals.

2019: Oncology Deal Activity Accelerates

Merck’s 2019 acquisition activity was heavily focused on oncology and therapeutics. The company acquired Immune Design, Tilos Therapeutics, Calporta Therapeutics, and ArQule.

Immune Design developed vaccines and therapeutics. Tilos created anti-LAP antibodies for cancer treatment. Calporta was developing selective small molecule agonists of TRPML1. ArQule was a clinical-stage biotechnology company focused on cancer therapeutics.

This cluster of deals shows Merck’s strategy of buying multiple scientific approaches rather than placing all pipeline risk on one program. In oncology, different mechanisms can succeed or fail depending on clinical results, patient selection, safety, and competitive dynamics.

2020: Antibody-Drug Conjugates and Clinical Oncology

In 2020, Merck acquired VelosBio for $2.8 billion and OncoImmune for $425.0 million.

VelosBio was a next-generation oncology company developing antibody-drug conjugates for hematological cancers. Antibody-drug conjugates became a major area of interest because they combine targeting mechanisms with cancer-killing payloads.

OncoImmune added clinical-stage biopharmaceutical programs for cancer treatment. Together, the 2020 acquisitions continued Merck’s strategy of investing in oncology innovation.

2021: Autoimmune Disease and Biotherapeutics

In 2021, Merck acquired Pandion Therapeutics for $1.9 billion and Acceleron Pharma for $11.5 billion.

Pandion developed modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases. Acceleron developed, manufactured, and commercialized novel biotherapeutics.

Acceleron was the largest listed acquisition in Merck’s record. It was a major strategic move and showed Merck’s willingness to make large bets on biopharmaceutical platforms.

2022: Bone Marrow Disease Therapeutics

In 2022, Merck acquired Imago BioSciences for $1.4 billion. Imago was a clinical-stage biopharmaceutical company developing drugs for proliferative diseases of the bone marrow.

This deal expanded Merck’s pipeline in hematology and rare or serious blood-related diseases. It also continued the pattern of acquiring specialist biotech companies with targeted development programs.

2023: Precision Medicine and Immunology With Prometheus

In 2023, Merck acquired Prometheus Biosciences for $10.8 billion. Prometheus developed pharmaceutical and diagnostic products designed to help physicians individualize patient care.

This was one of Merck’s largest acquisitions. It strengthened the company’s position in precision medicine and immune-mediated diseases. The deal also reflected the growing importance of diagnostics and patient selection in drug development.

2024: Eye Disease, DNA Modification, and Biopharma Assets

In 2024, Merck acquired Abceutics, Eyebiotech, and Modifi Bio. These transactions expanded the company’s exposure to ophthalmology, biopharmaceutical technology, and novel cancer therapeutics.

Eyebiotech, acquired for $3.0 billion, specialized in therapies for eye diseases. Modifi Bio, acquired for $1.3 billion, was focused on direct DNA modification and novel cancer therapeutics.

The 2024 acquisitions show Merck expanding across multiple scientific frontiers rather than relying only on one disease area.

2025: Respiratory Expansion With Verona Pharma

In 2025, Merck announced the acquisition of Verona Pharma for approximately $10 billion. Verona was focused on chronic respiratory diseases, and the deal added Ohtuvayre to Merck’s cardio-pulmonary disease portfolio. Merck announced completion of the transaction in October 2025.

This deal was strategically important because it diversified Merck into respiratory medicine at a time when large pharmaceutical companies were actively searching for new growth drivers. It also gave Merck a commercial respiratory asset rather than only a long-term research program.

Biggest Merck Acquisitions by Deal Value

Merck’s largest acquisitions show where the company has made its biggest strategic commitments.

The ranking shows that Merck’s largest deals are concentrated in biotechnology and therapeutic expansion. Acceleron, Prometheus, Verona, Eyebiotech, VelosBio, ArQule, Pandion, Imago, and Afferent all fit the science-led acquisition model.

Most Common Acquisition Categories

Merck acquisitions are heavily concentrated in biotechnology, health care, medical, therapeutics, and pharmaceutical businesses.

This category mix shows that Merck’s M&A strategy is driven by science, pipeline depth, and therapeutic diversification.

Strategic Lessons From Merck Acquisitions

Biotechnology Is the Main Engine

Merck acquisitions show that biotechnology is the company’s dominant M&A category. This reflects how modern pharmaceutical innovation increasingly comes from smaller biotech companies.

Large pharmaceutical companies often acquire biotech firms once their science has matured enough to justify a strategic investment. Merck’s acquisition history follows that pattern.

Oncology Has Been a Persistent Theme

Many Merck acquisitions are tied to cancer treatment. OncoEthix, cCAM Biotherapeutics, Rigontec, Tilos Therapeutics, ArQule, VelosBio, OncoImmune, and Modifi Bio all connect to oncology or cancer-related therapeutics.

This is not accidental. Oncology has been one of the most valuable and scientifically active areas in global medicine.

Diversification Is Becoming More Important

The Verona Pharma deal shows Merck expanding into respiratory disease. Eyebiotech added eye disease therapies. Pandion added autoimmune and inflammatory disease programs. Antelliq added animal intelligence solutions.

These deals show Merck building beyond one therapeutic pillar.

How Merck Acquisitions Fit Its Business Model

Merck’s business model depends on discovering, developing, manufacturing, and commercializing medicines and vaccines. Acquisitions fit this model because they help the company add drug candidates, scientific platforms, commercial assets, and disease-area expertise.

A biotech company may have a promising medicine but lack global commercialization capacity. Merck can bring regulatory experience, clinical development resources, manufacturing scale, and international market reach.

This model is especially important in pharmaceuticals because patent timelines are limited. Companies must constantly refresh their pipelines. M&A helps Merck reduce dependence on any one product franchise and build future growth options.

The acquisition record shows a balance of near-term and long-term assets. Verona Pharma added an approved COPD treatment. Prometheus, Acceleron, and Eyebiotech added major therapeutic platforms. Earlier oncology deals added discovery and clinical-stage programs.

Financial and Ownership Context

Merck completed 29 acquisitions from 1993 to 2025. Total disclosed deal value was about $67.4 billion, with an average disclosed deal size of approximately $2.3 billion.

The average deal size is high because Merck has completed several multibillion-dollar acquisitions. Acceleron, Prometheus, Verona, Eyebiotech, VelosBio, ArQule, Antelliq, and Pandion all required major capital commitments.

The Verona Pharma transaction was valued at approximately $10 billion, with Merck paying $107 per American Depositary Share, each representing eight Verona ordinary shares.

This financial pattern shows that Merck is willing to pay significant premiums for assets that fit its pipeline strategy. However, large biotech acquisitions carry risk. Clinical results, regulatory approvals, commercial uptake, pricing, reimbursement, and competitive positioning all affect long-term value.

Competitive Impact of Merck Acquisitions

Merck acquisitions strengthened the company’s competitive position by expanding its pipeline and reducing dependence on a narrower set of growth drivers.

In oncology, Merck used acquisitions to add novel mechanisms and therapeutic approaches. In immunology, Prometheus and Pandion strengthened exposure to immune-mediated diseases. In respiratory care, Verona added Ohtuvayre and expanded Merck’s cardio-pulmonary portfolio. In ophthalmology, Eyebiotech gave the company a stronger position in eye disease.

The acquisitions also improve Merck’s ability to compete with other large pharmaceutical companies for future growth categories. Pharma competition is not only about current sales. It is also about pipeline quality, patent protection, differentiation, and clinical data.

However, the competitive environment is intense. Other global drugmakers are also buying biotech companies, especially in oncology, immunology, rare diseases, respiratory medicine, and precision medicine.

Advantages of the Acquisition Strategy

Stronger Pipeline

Acquisitions help Merck add clinical-stage assets, approved medicines, and research platforms that can support future growth.

Therapeutic Diversification

Deals in respiratory disease, ophthalmology, autoimmune disease, chronic pain, oncology, and animal health reduce dependence on one therapeutic category.

Access to Specialist Science

Biotech acquisitions give Merck access to scientific teams, patents, research platforms, and disease-area expertise.

Faster Entry Into Growth Markets

Buying a company can help Merck enter a therapeutic market faster than building from scratch.

Strategic Response to Patent Risk

M&A can help offset future patent expirations by adding new revenue opportunities and pipeline candidates.

Disadvantages of the Acquisition Strategy

Clinical Trial Risk

Many biotech acquisitions depend on drugs still in development. If clinical trials fail, the acquisition value can fall sharply.

High Valuation Risk

Biotech assets can be expensive, especially when several large pharma companies are competing for the same targets.

Regulatory Risk

Drug candidates must pass regulatory review. Delays, safety issues, or rejection can reduce expected value.

Commercial Uncertainty

Even approved medicines must gain physician adoption, reimbursement, and patient access. Commercial success is not guaranteed.

Integration Risk

Scientific teams, research cultures, manufacturing systems, and commercial operations must be integrated carefully.

Case Studies of Major Merck Acquisitions

Acceleron Pharma

Acceleron Pharma was Merck’s largest listed acquisition, valued at $11.5 billion. Acceleron developed, manufactured, and commercialized novel biotherapeutics.

The deal was important because it expanded Merck’s specialty medicine pipeline and gave the company access to biologic drug development capabilities. It also showed Merck’s willingness to make large bets on biopharmaceutical innovation.

Prometheus Biosciences

Prometheus Biosciences was acquired for $10.8 billion in 2023. The company developed pharmaceutical and diagnostic products to help physicians individualize patient care.

This acquisition strengthened Merck’s position in precision medicine. It also reflected the growing value of pairing diagnostics with therapies so that the right patients can be matched to the right treatments.

Verona Pharma

Verona Pharma was acquired for approximately $10 billion in 2025. The acquisition added Ohtuvayre, a first-in-class COPD maintenance treatment for adults, to Merck’s portfolio.

This deal was strategically important because it moved Merck deeper into cardio-pulmonary and respiratory medicine. It also gave the company a commercial asset in a large disease market rather than only a preclinical or early-stage pipeline program.

Eyebiotech

Eyebiotech was acquired for $3.0 billion in 2024. The company specialized in therapies for eye diseases.

This acquisition gave Merck a stronger position in ophthalmology, a field where biologics, gene-related approaches, and targeted therapies continue to attract investment.

VelosBio

VelosBio was acquired for $2.8 billion in 2020. The company developed novel antibody-drug conjugates for hematological cancers.

This deal fit Merck’s oncology strategy and gave it exposure to a highly active drug class. Antibody-drug conjugates have become an important area of cancer treatment because they aim to deliver potent therapies more selectively.

Common Mistakes When Analyzing Merck Acquisitions

Looking Only at Deal Size

Large deals attract attention, but smaller acquisitions can also add important science. Early-stage oncology assets or specialist platforms may become valuable even if the initial purchase price is modest.

Ignoring Pipeline Risk

A biotech acquisition is not guaranteed to succeed. Investors should consider clinical trial stage, regulatory risk, safety profile, competition, and commercial potential.

Treating All Biotech Deals as Similar

Biotechnology is a broad category. Oncology antibodies, respiratory drugs, ophthalmology therapies, animal intelligence systems, and autoimmune proteins have different risk profiles.

Forgetting Patent Pressure

Pharma M&A often responds to future patent expirations. Analysts should consider how acquisitions support long-term revenue diversification.

Confusing Scientific Promise With Market Success

A drug can be scientifically promising but commercially limited if reimbursement is weak, competition is strong, or adoption is slow.

Lessons for Business Owners and Investors

Merck’s acquisition history offers several lessons.

First, large pharmaceutical companies rely heavily on external innovation. Biotech startups and clinical-stage companies can become valuable acquisition targets if their science addresses major unmet needs.

Second, therapeutic focus matters. Merck repeatedly invested in oncology, immunology, respiratory disease, ophthalmology, chronic pain, and animal health.

Third, timing is critical. Buying too early may increase scientific risk. Buying too late may raise valuation. The best acquisition timing balances risk and price.

Fourth, approved assets can be especially valuable. Verona Pharma gave Merck a commercial COPD medicine, which is different from buying only early-stage research.

Finally, successful pharma M&A depends on more than buying a promising drug. It requires clinical execution, regulatory strategy, manufacturing, physician education, payer access, and global commercialization.

Key Takeaways

• Merck completed 29 acquisitions from 1993 to 2025.
• Total disclosed deal value was about $67.4 billion.
• The average disclosed acquisition size was approximately $2.3 billion.
• Biotechnology was the dominant category, with 26 deals.
• Health care accounted for 16 acquisitions.
• Medical businesses accounted for 9 acquisitions.
• The largest listed acquisition was Acceleron Pharma at $11.5 billion.
• Prometheus Biosciences and Verona Pharma were also major deals above $10 billion.
• The most recent listed acquisition was Verona Pharma, announced in July 2025 for approximately $10 billion.
• Merck’s acquisition strategy focuses on oncology, respiratory disease, immunology, ophthalmology, chronic pain, animal health, and therapeutic innovation.
• Major risks include clinical failure, regulatory delays, high valuations, reimbursement limits, and integration challenges.
• Merck acquisitions show how pharma companies use M&A to strengthen pipelines and diversify future growth.

Frequently Asked Questions

What are Merck acquisitions?

Merck acquisitions are companies or assets acquired by Merck to expand its biotechnology, pharmaceutical, healthcare, oncology, respiratory, ophthalmology, immunology, and therapeutic pipeline.

How many acquisitions has Merck made?

Merck has made 29 acquisitions across the period from 1993 to 2025.

What is the total value of Merck acquisitions?

The total disclosed value of Merck acquisitions is about $67.4 billion.

What is Merck’s average acquisition size?

Merck’s average disclosed acquisition size is approximately $2.3 billion.

What was Merck’s most recent listed acquisition?

Merck’s most recent listed acquisition is Verona Pharma, announced in July 2025 for approximately $10 billion. Merck later said it completed the transaction in October 2025.

What is Merck’s biggest listed acquisition?

The largest listed Merck acquisition is Acceleron Pharma, announced in September 2021 for $11.5 billion.

Why did Merck acquire Verona Pharma?

Merck acquired Verona Pharma to add Ohtuvayre and expand its cardio-pulmonary and respiratory disease portfolio.

Which sectors dominate Merck acquisitions?

Merck acquisitions are dominated by biotechnology, health care, medical, therapeutics, and pharmaceutical businesses.

Why are biotechnology acquisitions important to Merck?

Biotechnology acquisitions help Merck access external innovation, scientific platforms, clinical-stage assets, and potential future medicines.

What are the risks of Merck’s acquisition strategy?

The main risks include clinical trial failure, regulatory delays, high acquisition prices, integration challenges, reimbursement limits, and uncertain commercial adoption.

Conclusion

Merck acquisitions show how a global biopharmaceutical company uses M&A to strengthen its pipeline, diversify therapeutic exposure, and prepare for future growth. From 1993 to 2025, Merck completed 29 acquisitions with total disclosed deal value of about $67.4 billion. Most of those deals were concentrated in biotechnology, health care, medical science, therapeutics, and pharmaceuticals.

The company’s largest acquisitions reveal its strategic priorities. Acceleron added biotherapeutics. Prometheus strengthened precision medicine and immunology. Verona Pharma expanded Merck into respiratory disease with Ohtuvayre. Eyebiotech added ophthalmology. VelosBio, ArQule, Tilos, Rigontec, cCAM, and OncoEthix reinforced oncology.

For business owners, investors, and healthcare analysts, Merck acquisitions offer a clear lesson: in modern pharma, external innovation is not optional. Large drugmakers must constantly search for promising science, manage patent pressure, and build future growth beyond existing blockbusters. Merck’s M&A record shows a company using acquisitions to follow the science, strengthen its pipeline, and compete in some of medicine’s most important therapeutic markets.

Disclaimer: This article is for informational and educational purposes only. It is not investment advice, financial advice, or a recommendation to buy or sell any security. Always conduct your own research and consider speaking with a qualified financial adviser before making investment decisions.

Read Also: Medtronic Acquisitions: How Medtronic Built Its Business Through M&A